Suppr超能文献

大鼠中的混合异基因嵌合体。主要血管化心脏同种异体移植物的供体特异性移植耐受且无慢性排斥反应。

Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.

作者信息

Colson Y L, Zadach K, Nalesnik M, Ildstad S T

机构信息

Department of Surgery, University of Pittsburgh, Pennsylvania 15261, USA.

出版信息

Transplantation. 1995 Nov 15;60(9):971-80.

PMID:7491703
Abstract

Graft loss secondary to chronic rejection remains a major source of morbidity and mortality in solid organ transplantation. Mixed chimerism has been suggested as one potential approach to overcome this limitation. Until now, whether long-term tolerance for primarily vascularized allografts can be achieved with mixed chimerism has not been adequately assessed due to technical limitations in the mouse and the inability to establish a reliable model of mixed chimerism in the rat. We now report that stable multilineage mixed hematopoietic chimerism can be achieved following the transplantation of a mixture of T cell-depleted syngeneic and allogeneic bone marrow cells into myeloablated rat recipients using a number of MHC plus minor antigen-disparate donor and recipient strain combinations (F344+WF-->F344, F344+ACI-->F344, WF+F344-->WF, and WF+ACI-->WF). Ninety-one percent of animals engrafted with a level of lymphoid chimerism ranging between 12% and 93% (73.3 +/- 4.8%). Peripheral blood lymphocyte chimerism remained stable for up to 13 months after reconstitution. Multilineage chimerism for lymphoid (T and B cells) and myeloid (granulocyte and macrophage) lineages was present, which suggests that engraftment of the pluripotent rat stem cell had occurred. There was no clinical or histologic evidence of graft-versus-host disease. Donor-specific skin (mean survival time [MST] > or = 177 days) and primarily vascularized cardiac (MST > or = 213 days) grafts were accepted without evidence for acute or chronic rejection. In contrast, MHC-disparate third-party skin (MST = 14 days) and cardiac grafts (MST = 13 days) were rapidly rejected. The tolerance was systemic, since donor-specific tolerance was present in vitro as assessed by the mixed lymphocyte proliferation assay. These data suggest that mixed chimerism prevents graft loss secondary to chronic rejection in skin as well as primarily vascularized grafts. Furthermore, a rat model for mixed allogeneic chimerism may provide insight into the mechanisms involved in tolerance induction for a variety of allografts (lungs, small bowel, limb, etc.) not readily transplantable in mouse recipients.

摘要

在实体器官移植中,慢性排斥导致的移植物丢失仍是发病和死亡的主要原因。混合嵌合体被认为是克服这一局限的一种潜在方法。到目前为止,由于小鼠存在技术限制以及无法在大鼠中建立可靠的混合嵌合体模型,使用混合嵌合体能否实现对主要血管化同种异体移植物的长期耐受尚未得到充分评估。我们现在报告,使用多种主要组织相容性复合体(MHC)加次要抗原不相合的供体和受体品系组合(F344+WF→F344、F344+ACI→F344、WF+F344→WF和WF+ACI→WF),将去除T细胞的同基因和异基因骨髓细胞混合物移植到经骨髓消融的大鼠受体后,可实现稳定的多谱系混合造血嵌合体。91%的动物植入的淋巴细胞嵌合水平在12%至93%之间(73.3±4.8%)。重建后外周血淋巴细胞嵌合体在长达13个月的时间内保持稳定。存在淋巴细胞(T细胞和B细胞)和髓细胞(粒细胞和巨噬细胞)谱系的多谱系嵌合体,这表明多能大鼠干细胞已发生植入。没有移植物抗宿主病的临床或组织学证据。供体特异性皮肤(平均存活时间[MST]≥177天)和主要血管化心脏(MST≥213天)移植物被接受,没有急性或慢性排斥的证据。相比之下,MHC不相合的第三方皮肤(MST=14天)和心脏移植物(MST=13天)被迅速排斥。这种耐受是全身性的,因为通过混合淋巴细胞增殖试验评估,体外存在供体特异性耐受。这些数据表明,混合嵌合体可防止皮肤以及主要血管化移植物因慢性排斥导致的移植物丢失。此外,大鼠混合同种异体嵌合体模型可能有助于深入了解对多种在小鼠受体中不易移植的同种异体移植物(肺、小肠、肢体等)诱导耐受所涉及的机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验